NFKB1 and ovarian cancer: Furthermore, miR-146a was also shown to target and reduce MyD88 expression, thus inhibiting the NF-κB activation in epithelial ovarian cancer, and directly regulating the sensitivity of ovarian cancer cells to drug therapy (42).